Michael Seep
Family Medicine · Lake Charles, LANPI 1013993484
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.9% of the total across 206 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 17.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,118 and has fallen 90.1% since, to $111 in 2023.
Across 206 payments — averaging $13.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$469
- Pfizer$316
- Lilly USA, LLC$243
- Bayer$192
- Amgen$161
- Novo Nordisk$146
- plus $1K from 19 others
Across 1,141 payments — averaging $7941.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$3.6M
- AstraZeneca$3.2M
- AbbVie$1.3M
- Janssen Research & Development, LLC$563K
- Sanofi US Services Inc.$112K
- Pfizer$88K
- plus $227K from 14 others
What the payments were for
- Food & beverage$2,70798%
- Gifts$592%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 38 | $469 |
| Pfizer | 35 | $316 |
| Lilly USA, LLC | 17 | $243 |
| Bayer | 10 | $192 |
| Amgen | 20 | $161 |
| Novo Nordisk | 10 | $146 |
| AstraZeneca | 11 | $137 |
| Astellas Pharma US Inc | 8 | $131 |
| Urovant Sciences Inc | 1 | $111 |
| Johnson & Johnson | 7 | $102 |
| Merck | 6 | $99 |
| Novartis | 7 | $95 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $76 |
| Biohaven Pharmaceuticals, Inc. | 4 | $74 |
| Mannkind Corporation | 1 | $59 |
| Boehringer Ingelheim | 4 | $55 |
| Abbott | 3 | $54 |
| Amarin Pharma, Inc. | 4 | $54 |
| Esperion Therapeutics, Inc. | 3 | $41 |
| Sunovion Pharmaceuticals Inc. | 2 | $37 |
| Sanofi-aventis U.S. LLC | 2 | $27 |
| Kowa Pharmaceuticals America, Inc. | 2 | $25 |
| Teva Pharmaceuticals USA, Inc. | 2 | $24 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Almatica Pharma LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GEMTESA$111
How this compares
$2,767 in reported general payments places this provider in the 70th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in Lake Charles
- Joshua WhatleyLake Charles$17K
- Robert VangossenLake Charles$14K
- Ryan ForetLake Charles$13K
- Keith LechtenbergLake Charles$13K
- Christine SmithBaton Rouge$185K
- Thomas DansbyMonroe$169K
- Michael FlemingShreveport$165K
- Robert St AmantGonzales$156K
- William HathawaySpringhill$105K
- Cesar GonzalesWest Monroe$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.